Table 2.
ZEB1 and ZEB2 confer resistance to chemotherapy and radiotherapy
| Evidence | Resistance | Reference | |
|---|---|---|---|
| ZEB1 | Pancreatic carcinoma cell lines | Gemcitabine 5-Fluorouracil Cisplatin | [97, 120, 121] |
| ZEB1 | Breast carcinoma cell lines | Doxorubicin | [123] |
| ZEB1 | Non-small cell lung carcinoma cell lines | Gefitinib | [119] |
| ZEB1 | Head and neck squamous carcinoma cell lines | Ertotinib | [122] |
| ZEB2 | Primary transitional cell carcinomas of the bladder (clinical evidence) | Radiotherapy | [98] |
| ZEB2 | Bladder carcinoma cell lines | Cisplatin UV radiation | [98] |
| ZEB2 | Squamous carcinoma cell lines | Cisplatin UV radiation | [98] |